Beth Ann G Coller

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. doi request reprint Dengue vaccines: progress and challenges
    Beth Ann G Coller
    Vaccines Research, WP17 2131, Merck and Company, 770 Sumneytown Pike, P O Box 4, West Point, PA 19486, United States
    Curr Opin Immunol 23:391-8. 2011
  2. pmc The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease
    Beth Ann G Coller
    Merck and Co, 770 Sumneytown Pike, West Point, PA 19486, United States
    Vaccine 29:7267-75. 2011
  3. doi request reprint Preclinical and clinical development of a dengue recombinant subunit vaccine
    Susan B Manoff
    Merck and Co, Inc, Kenilworth, NJ, United States
    Vaccine 33:7126-34. 2015

Collaborators

  • Danilo R Casimiro
  • Susan B Manoff
  • Sarah L George
  • D Elliot Parks
  • Vidya Pai
  • Linda Eggemeyer
  • Govindarajan Dhanasekaran
  • Timothy Martyak
  • Michele L Yelmene
  • Sheri A Dubey
  • Michele L Sausser
  • David E Clements
  • Andrew J Bett

Detail Information

Publications3

  1. doi request reprint Dengue vaccines: progress and challenges
    Beth Ann G Coller
    Vaccines Research, WP17 2131, Merck and Company, 770 Sumneytown Pike, P O Box 4, West Point, PA 19486, United States
    Curr Opin Immunol 23:391-8. 2011
    ....
  2. pmc The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease
    Beth Ann G Coller
    Merck and Co, 770 Sumneytown Pike, West Point, PA 19486, United States
    Vaccine 29:7267-75. 2011
    ..Based on the promising preclinical data, the recombinant DEN-80E proteins have now advanced into clinical studies. An overview of the relevant preclinical data for these recombinant proteins is presented in this review...
  3. doi request reprint Preclinical and clinical development of a dengue recombinant subunit vaccine
    Susan B Manoff
    Merck and Co, Inc, Kenilworth, NJ, United States
    Vaccine 33:7126-34. 2015
    ..Both the 10μg DEN1-80E and the 50μg DEN1-80E formulations with Alhydrogel™ were generally well tolerated. ..